Please ensure Javascript is enabled for purposes of website accessibility

Could Tilray Be a Millionaire-Maker Stock?

By David Jagielski - Mar 11, 2021 at 7:11AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Its shares are up by more than 300% since early November.

Every investor would love to watch one of their stock holdings expand from a relatively small position to a million-dollar-plus value. But gains like that don't happen often -- and they're even less likely to happen to you if you don't start by picking some companies for your portfolio that have significant growth potential.

One sector that's full of that type of potential? Cannabis. According to research company BDSA, the global legal cannabis market will be worth $55.9 billion by 2026. To reach that size between now and then, it will have to grow at a compound annual rate of more than 17%.

Trimming a cannabis plant.

Image source: Getty Images.

Tilray (TLRY) could benefit from a lot of that growth. It's already one of the top cannabis companies in the world, and once its merger with Aphria (APHA) is completed later this year, it will become even bigger. But could investing in Tilray make you a millionaire?

How Tilray could make you rich

Tilray may have already made some millionaires back in 2018 when its stock (briefly) skyrocketed from below $25 a share to above $200. Investors jumped on the stock following news that the company had obtained approval from the Drug Enforcement Agency to import cannabis into the U.S. for a medical study. But the hype was short-lived, and Tilray's stock slid from that peak as investors realized that didn't mean the company was actually going to import and sell pot in the U.S. market.

Today, the stock is nowhere near those levels. In fact, after languishing in the single digits for much of 2020, it's now trading at about $24 -- in the same neighborhood where it was in the summer of 2018 prior to the aforementioned surge.

However, marijuana reform continues to make progress in the U.S. Four more states passed legalization referendums in November. In Virginia, a bill that will legalize pot for recreational use in 2024 awaits the governor's signature, and New York's legislature is also considering its own bills this year. As such, there could continue to be lots of bullishness in the sector. 

Year to date, shares of Tilray are already up around 200% -- dwarfing the gains of the sector-benchmark Horizons Marijuana Life Sciences ETF, which is up 57%. And if you measure from the start of November 2020 -- just before the U.S. election -- Tilray's stock is up by more than 320%, while the Horizons ETF has doubled.

The apparent takeaway from this is that signs of progress on the legalization front, rather than strong sales and profit numbers in the near term, will be what lifts cannabis stocks into the stratosphere. And now that Tilray is merging with Aphria, it will become the largest cannabis company in Canada. It could have the most to gain if the U.S. legalizes marijuana (with the possible exception of Canopy Growth, which has a tentative merger deal arranged with Acreage Holdings that is contingent on U.S. federal legalization).

Over the trailing 12 months, Canopy Growth generated 506 million Canadian dollars in revenue. However, Aphria alone generated CA$602 million over its last four quarters. When that's added to Tilray's revenue of roughly CA$265 million, the combined entity will be far ahead of what used to be the largest cannabis company in Canada.

If the U.S. legalizes marijuana, top cannabis stocks like Tilray will take off.

But the stock isn't a risk-free investment

The problem right now is that the euphoric rise of pot stocks, particularly Canadian ones, in the wake of the U.S. election seems to suggest a high degree of optimism surrounding legalization's prospects. Consider that Canopy Growth CEO David Klein is so confident that he went as far as to say publicly that he expects his company will likely be operating in the U.S. this year

Yet despite those lofty expectations, the most that President Joe Biden has hinted at in the past is that he favors decriminalizing marijuana, not fully legalizing it. And decriminalization on its own won't be enough to let Canadian cannabis producers sell their products in the U.S. 

If investors get concerned that legalization isn't going to happen in the near future, Tilray and other Canadian pot stocks could quickly give back much of their recent gains. Without the updraft of marijuana legalization hype lifting the price, Tilray shares are unlikely to make any retail investors into millionaires.

Also worth noting: While Tilray will boast that it hit its target of adjusted EBITDA profitability in the fourth quarter, that isn't its true accounting income. Over the past four quarters, the company has amassed net losses of more than CA$340 million. And while Aphria also posted an adjusted EBITDA profit for the seventh straight quarter when it released its fiscal second-quarter results on Jan. 14, its net loss over the six-month period ending Nov. 30 stood at CA$125.7 million.

The reality is that these still aren't truly profitable businesses, and they are relying on non-GAAP numbers to make their cases to investors. This is why I am not bullish on their results or their share prices.

Should you invest in Tilray?

If I thought investing in Tilray would make me a millionaire, I would have bought shares in it already. But I haven't. That's partly because I'm not confident that full legalization of recreational marijuana will take place in the U.S. during the Biden administration. The cannabis industry has a way of getting ahead of itself on the optimism front, which can do more harm than good over the long run as it inflates expectations.

If you want to invest in the U.S. pot market, you are probably better off picking up shares of a multistate operator that already has a strong presence in it. CuraleafCresco Labs, and Trulieve are just some examples of companies that are already dominating the industry.

Tilray may generate some good returns over the long run, especially if it and Aphria can continue to strengthen their top and bottom lines. But if you are expecting this stock to turn tens of thousands of dollars into a million or more, you will likely be disappointed.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Tilray Stock Quote
Tilray
TLRY
Canopy Growth Stock Quote
Canopy Growth
CGC
$5.85 (4.65%) $0.26
Horizons Marijuana Life Sciences Index ETF Stock Quote
Horizons Marijuana Life Sciences Index ETF
HMLSF
$3.39 (-0.13%) $0.00
Curaleaf Holdings, Inc. Stock Quote
Curaleaf Holdings, Inc.
CURLF
$5.80 (3.39%) $0.19
Aphria Stock Quote
Aphria
APHA
Acreage Holdings, Inc. Stock Quote
Acreage Holdings, Inc.
ACRGF
Trulieve Cannabis Stock Quote
Trulieve Cannabis
TCNNF
$14.78 (2.84%) $0.41
Cresco Labs Inc. Stock Quote
Cresco Labs Inc.
CRLBF
$3.94 (2.07%) $0.08

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
327%
 
S&P 500 Returns
116%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.